Spermosens AB (publ)
Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorpora… Read more
Spermosens AB (publ) (9R5) - Total Assets
Latest total assets as of September 2025: €35.59 Million EUR
Based on the latest financial reports, Spermosens AB (publ) (9R5) holds total assets worth €35.59 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Spermosens AB (publ) - Total Assets Trend (2021–2024)
This chart illustrates how Spermosens AB (publ)’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Spermosens AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2024)
Spermosens AB (publ)'s total assets of €35.59 Million consist of 5.7% current assets and 94.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.1% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €24.34 Million | 78.4% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Spermosens AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Spermosens AB (publ)'s current assets represent 5.7% of total assets in 2024, a decrease from 28.8% in 2021.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2024, down from 26.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 78.0% of total assets, an increase from 71.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 78.4% of total assets.
Spermosens AB (publ) Competitors by Total Assets
Key competitors of Spermosens AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Spermosens AB (publ) - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Spermosens AB (publ) generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Spermosens AB (publ) is currently not profitable relative to its asset base.
Spermosens AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.27 | 0.25 | 0.25 |
| Quick Ratio | 9.27 | 0.25 | 0.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €8.80 Million | € -2.25 Million | € -2.25 Million |
Spermosens AB (publ) - Advanced Valuation Insights
This section examines the relationship between Spermosens AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.20 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 18.9% |
| Total Assets | €31.04 Million |
| Market Capitalization | $517.28K USD |
Valuation Analysis
Below Book Valuation: The market values Spermosens AB (publ)'s assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Spermosens AB (publ)'s assets grew by 18.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Spermosens AB (publ) (2021–2024)
The table below shows the annual total assets of Spermosens AB (publ) from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €31.04 Million | +18.92% |
| 2023-12-31 | €26.11 Million | +170.13% |
| 2022-12-31 | €9.66 Million | -62.37% |
| 2021-12-31 | €25.68 Million | -- |